ClearPoint NeuroCLPT
CLPT
About: ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, and ClearPoint Therapeutic Solutions.
Employees: 107
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
99% more capital invested
Capital invested by funds: $38.6M [Q2] → $76.6M (+$38.1M) [Q3]
46% more call options, than puts
Call options by funds: $1.02M | Put options by funds: $695K
5% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 21
1.32% less ownership
Funds ownership: 26.08% [Q2] → 24.76% (-1.32%) [Q3]
9% less funds holding
Funds holding: 86 [Q2] → 78 (-8) [Q3]
32% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 22
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$20
12%
upside
Avg. target
$25
39%
upside
High target
$30
67%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
B. Riley Securities Neil Chatterji 100% 1-year accuracy 2 / 2 met price target | 12%upside $20 | Buy Maintained | 28 Jan 2025 |
Lake Street Frank Takkinen 63% 1-year accuracy 12 / 19 met price target | 67%upside $30 | Buy Maintained | 21 Jan 2025 |
Financial journalist opinion
Based on 3 articles about CLPT published over the past 30 days
Positive
Zacks Investment Research
2 weeks ago
CLPT Stock Gains on FDA Clearance for Navigation Software Version 3.0
ClearPoint achieves FDA 510(k) clearance for its Navigation Software Version 3.0, designed to standardize cell and gene therapy delivery in the United States.
Neutral
Accesswire
2 weeks ago
ClearPoint Neuro Announces FDA Clearance for ClearPoint Navigation Software Version 3.0
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 27, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has received 510(k) clearance for its ClearPoint Navigation Software Version 3.0. "As we prepare for the wave of new patients that will be treated with cell and gene therapies in the years ahead, it is crucial that ClearPoint helps healthcare providers be ready by providing simplified workflows, offering solutions to increase surgical capacity and expanding access to our hardware and software," commented Joe Burnett, President and CEO at ClearPoint Neuro.
Positive
Zacks Investment Research
3 weeks ago
ClearPoint Neuro (CLPT) Surges 22.5%: Is This an Indication of Further Gains?
ClearPoint Neuro (CLPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Positive
Zacks Investment Research
1 month ago
4 MedTech Stocks That Gained More Than 100% in 2024 With Room to Run
Here are some strong MedTech stocks - DOCS, CLOV, CLPT and HIMS - that are expected to provide promising gains.
Neutral
Accesswire
2 months ago
ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain
Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United States SOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the U.S. Food and Drug Administration (FDA) has granted marketing authorization for the SmartFlow Neuro Cannula using the De Novo pathway. The SmartFlow Neuro Cannula is intended for intraputaminal administration of PTC Therapeutics' gene therapy KEBILIDI™ (eladocagene exuparvovec-tneq) for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency.
Negative
Seeking Alpha
3 months ago
ClearPoint Neuro: Near-Term Volatility Is No Concern
ClearPoint Neuro reported strong YoY growth in Q3, but the stock reacted negatively, probably due to its high valuation and weak sequential growth. Volatile performance should be expected in the near term due to the company's size and the immaturity of growth initiatives. ClearPoint's margins are improving, and cash burn is minimal, which should ease concerns about dilution.
Neutral
Seeking Alpha
3 months ago
ClearPoint Neuro, Inc. (CLPT) Q3 2024 Earnings Call Transcript
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Joe Burnett - President & Chief Executive Officer Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Operator Greetings, and welcome to the ClearPoint Neuro, Inc. Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode.
Negative
Zacks Investment Research
3 months ago
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Tops Revenue Estimates
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.20 per share a year ago.
Neutral
Accesswire
3 months ago
ClearPoint Neuro Reports Third Quarter 2024 Results
Achieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million SOLANA BEACH, CA / ACCESSWIRE / November 7, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2024. Third Quarter Highlights Reported quarterly revenue of $8.1 million, a 41% year-over-year increase; Accelerated growth of SmartFrame OR™ platform and ClearPoint Prism® Laser Therapy System, contributing to record navigation and device revenue of $2.9 million, a 53% year-over-year increase; Overall product revenue, including biologics and drug delivery, more than doubled year-over-year, growing 127% to $5.5 million; Activated five new global centers in the third quarter for a total of 19 new centers so far this year; approximately three times our historic activation rate; Continued patient enrollment in numerous cell and gene therapy trials for partners selected in FDA expedited review programs across multiple indications; Full early repayment of the principal amount and interest on a $10 million convertible note leaving the Company with no outstanding debt as of September 30, 2024; Quarterly operational cash burn reduced to $1.2 million, a 33% year-over-year decrease; and Reported cash and cash equivalents totaling $21.6 million as of September 30, 2024.
Neutral
Accesswire
3 months ago
ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024
President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast Today SOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced participation in multiple investor conferences and interview formats including Bloomberg Intelligence Vanguards of Healthcare Podcast series published today. The link to the interview published this morning on Bloomberg can be found HERE.
Charts implemented using Lightweight Charts™